Partnering with Numerate when starting new projects can greatly accelerate generation of valuable IP.
The best way to validate the biological hypothesis behind a hot new target is to make compounds active against that target.
Starting with very small amounts of data, our platform can be used in early hit finding, as well as rapid lead identification to validate the target.
In particular, our platform can deliver:
First in-class compounds. There are large numbers of well understood, validated targets that have proven to be a challenge due to issues such as PK or selectivity; for example, BACE inhibitors.
Our technology can be used to hop out of the problematic scaffolds into ones more likely to yield a viable candidate.
Fast-followers. Often there are clearly understood flaws with current therapies. We can build on the available data about existing drugs to design a next-generation drug.
Flaws related to, for example, off-target effects or PK properties, can be addressed by our platform.
